Aghamohammadi Asghar, Kanegane Hirokazu, Moein Mostafa, Farhoudi Abolhasan, Pourpak Zahra, Movahedi Masoud, Gharagozlou Mohammad, Zargar Ali Akabar Amir, Miyawaki Toshio
Department of Clinical Pediatric Immunology, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Int J Hematol. 2003 Jul;78(1):45-7. doi: 10.1007/BF02983239.
Common variable immunodeficiency (CVID) is a highly heterogeneous disease with an unpredictable pattern. CVID appears to have an immunologic and clinical phenotype similar to some hereditary humoral immunodeficiencies, including X-linked lymphoproliferative disease (XLP). The differential diagnosis of CVID and XLP is clinically of importance, because the two diseases have markedly different prognoses and treatment. The recent identification of the XLP gene, known as SH2D1A, has permitted a definitive diagnosis of XLP. In this report, we describe a male patient with XLP who initially received a diagnosis of CVID and developed a fatal course. Using genetic analysis, we confirmed that the patient harbored the SH2D1A gene mutation. The results support the notion that the possibility of a SH2D1A gene mutation should be considered in hypogammaglobulinemic male patients before a diagnosis of CVID is made.
普通可变型免疫缺陷(CVID)是一种高度异质性疾病,其模式不可预测。CVID似乎具有与某些遗传性体液免疫缺陷相似的免疫和临床表型,包括X连锁淋巴增殖性疾病(XLP)。CVID和XLP的鉴别诊断在临床上具有重要意义,因为这两种疾病的预后和治疗明显不同。最近对XLP基因(即SH2D1A)的鉴定使得能够对XLP进行明确诊断。在本报告中,我们描述了一名患有XLP的男性患者,他最初被诊断为CVID并发展为致命病程。通过基因分析,我们证实该患者携带SH2D1A基因突变。结果支持这样一种观点,即在诊断CVID之前,对于低丙种球蛋白血症男性患者应考虑存在SH2D1A基因突变的可能性。